Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Arbutus Biopharma (ABUS) Misses Q2 EPS by 7c
August 5, 2019 7:37 AM EDTArbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.46), $0.07 worse than the analyst estimate of ($0.39).
Appointed William Collier, with decades of leadership experience in antivirals, President & CEOAnnounced preliminary Phase 1a/1b clinical trial results demonstrating that AB-506 is a potent capsid inhibitor... More